Get the Stockscreener App
3.44
1.43%
-0.05
Pre-market:
3.48
0.04
+1.16%
Arbutus Biopharma Corp stock is traded at $3.44, with a volume of 612.89K.
It is down -1.43% in the last 24 hours and down -17.11% over the past month.
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
See More
Previous Close:
$3.49
Open:
$3.53
24h Volume:
612.89K
Relative Volume:
0.57
Market Cap:
$649.41M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-7.4783
EPS:
-0.46
Net Cash Flow:
$-78.92M
1W Performance:
-5.75%
1M Performance:
-17.11%
6M Performance:
+12.05%
1Y Performance:
+86.96%
1-Day Range:
$3.42
$3.5399
1-Week Range:
$3.42
$3.81
52-Week Range:
$1.79
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ABUS | 3.44 | 649.41M | 12.99M | -74.39M | -78.92M | -0.46 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Arbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from Chardan Capital - MarketBeat
HC Wainwright Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment - MyChesCo
Arbutus Biopharma Announces Positive Data from Clinical Trials at AASLD – The Liver Meeting® 2024 - Defense World
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus - MyChesCo
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 16.0% in October - Defense World
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results - MyChesCo
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update - MarketBeat
Two Seas Capital LP Adjusts Stake in Arbutus Biopharma Corp - GuruFocus.com
Arbutus to Present at Jefferies London Healthcare Conference - Yahoo Finance
Creative Planning Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
HC Wainwright Has Negative Forecast for ABUS FY2024 Earnings - MarketBeat
HC Wainwright Expects Weaker Earnings for Arbutus Biopharma - Defense World
HC Wainwright Reaffirms “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Arbutus Biopharma 8-K Filing: Financial Results and Corporate Presentation Update - Defense World
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Earnings Call Transcript - Insider Monkey
JMP Securities Increases Arbutus Biopharma (NASDAQ:ABUS) Price Target to $5.00 - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
HC Wainwright Reaffirms Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... By GuruFocus - Investing.com Canada
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Arbutus Fades on Q4 Results - Baystreet.ca
Arbutus Biopharma earnings missed, revenue fell short of estimates - Investing.com
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arbutus Biopharma Corp Q3 2024 Earnings: EPS Loss of $0.10 Meets Estimates, Revenue Falls Short at $1.3 Million - GuruFocus.com
Arbutus: Q3 Earnings Snapshot - San Francisco Chronicle
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Arbutus Biopharma (ABUS) Set to Announce Earnings on Wednesday - MarketBeat
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance
SG Americas Securities LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Target of Unusually High Options Trading (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma Corp (ABUS) Stock: A Year of Declines and Increases - The InvestChronicle
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 5.7%Still a Buy? - MarketBeat
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLDThe Liver Meeting® 2024 - Yahoo Finance
Arbutus Biopharma announces officer retirement terms By Investing.com - Investing.com South Africa
Arbutus Biopharma announces officer retirement terms - Investing.com India
Arbutus Biopharma CSO Michael Sofia Announces Retirement Plans - TipRanks
Examining Arbutus Biopharma Corp (ABUS) stock is warranted - US Post News
Arbutus Biopharma Corp [ABUS] stock for 32,637 USD was sold by MANCHESTER KEITH S - Knox Daily
Balance Sheet Dive: Arbutus Biopharma Corp (ABUS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Top investors say Arbutus Biopharma Corp (ABUS) ticks everything they need - SETE News
XTX Topco Ltd Buys Shares of 17,038 Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Jefferies Upgrades Arbutus Biopharma Corp (ABUS) to a Buy from a Hold - Knox Daily
How to interpret Arbutus Biopharma Corp (ABUS)’s stock chart patterns - US Post News
Taking on analysts’ expectations and winning: Arbutus Biopharma Corp (ABUS) - SETE News
Arbutus Biopharma Corp (ABUS)’s Day in Review: Closing at 3.85, Up by 0.52 - The Dwinnex
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference - Yahoo Finance
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 8.3% in September - MarketBeat
Wall Street SWOT: Arbutus Biopharma stock navigates legal wins and pipeline focus - Investing.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 2.8% - MarketBeat
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):